Off the wire
• 5.0-magnitude quake hits U.S. state of Oklahoma  • S.Korean president's approval rating continues to fall despite apology  • India's main opposition chief Sonia Gandhi fails to chair party meeting due to health reasons  • NBA: Toronto continues three-point shooting woes in loss to Sacramento  • Infrared camera captures rare leopard in NW China  • More birds found in Beijing wetland reserve  • 1st LD Writethru: UN peacekeeper, two civilians killed in Mali  • Modi pitches for Make in India initiative to bolster trade ties with Britain  • S.Korea's opposition parties demand new parliament-proposed prime minister  • Indonesia registers 5.02 pct growth in Q3  
You are here: 　 Home

Merck opens China pharmaceutical plant

Xinhua, November 7, 2016 Adjust font size:

The world's leading biomedicine company Merck has opened a plant in Nantong, China's eastern Jiangsu Province, to produce pharmaceuticals on the country's Essential Drug List.

Merck has invested 170 million euros (188 million U.S. dollars) in the Nantong pharmaceutical plant, which had been under construction since 2013.

"By dedicating the largest manufacturing plant outside Europe to the production of pharmaceuticals to address widespread health care needs in China, Merck is connected to China more than ever," said Mark Horn, managing director of Merck's biopharma business, in China on Friday.

The Nantong plant will reach an annual output of up to 10 billion dosages of pharmaceuticals for the treatment of diabetes, cardiovascular disease and thyroid disorders by 2021.

The first batch of its pharmaceutical products will enter the market in the second half of 2017.

Merck has announced a further investment of 80 million euros in a life science center near the Nantong plant, which will produce high-purity inorganic salts, cell culture media products and ready-to-use media. Endi